Effect and safety of tamsulosin, the prostate specific alpha(1)-blocker, in the treatment of BPH (benign prostatic hyperplasia)

被引：2
作者：
Kawabe, K
机构：
[1] Department of Urology, Faculty of Medicine, The University of Tokyo, Tokyo
来源：
AKTUELLE UROLOGIE | 1996年 / 27卷
关键词：
BPH; alpha-blocker; alpha(1a)-receptor-subtype; tamsulosin;
D O I：
10.1055/s-2008-1055642
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Clinical trials of tamsulosin demonstrate that it is an effective treatment modality for the symptoms associated with BPH, and it has practically no effect on blood pressure at a dose of 0.2 mg. This is probably due to its selective affinity for the prostate, which may be due to the strong affinity of tamsulosin for the alpha(1a)-receptor subtype.
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [31] Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
    Gross, AJ
    Busse, M
    Leonard, J
    Schumacher, H
    PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (03) : 210 - 214
  • [32] Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
    A J Gross
    M Busse
    J Leonard
    H Schumacher
    Prostate Cancer and Prostatic Diseases, 2005, 8 : 210 - 214
  • [33] Assessing the Safety of Combined Therapy, Croton membranaceus and Tamsulosin, in the Self-Prescribed Treatment Protocol for Benign Prostatic Hyperplasia
    Gborsong, Cosmos
    Asare, George A.
    Ngala, Robert A.
    Obirikorang, Christian
    Ablakwa, Josephine
    Asiedu, Bernice
    Adjei, Samuel
    Afriyie, Osei
    Afriyie, Daniel
    Hossain, Mokbul
    Pervin, Munmun
    Alam, Md. Mahmudul
    Akter, Mst. Antora
    Rahman, Mohammed Habibur
    JOURNAL OF TOXICOLOGY, 2025, 2025 (01)
  • [34] Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (Tamsulosin) in the treatment of benigh prostatic hyperplasia:: a 1-year randomized international study.
    Debruyne, F
    Koch, G
    Boyle, P
    Da Silva, FC
    Gillenwater, JG
    Hamdy, FC
    Perrin, P
    Teillac, P
    Vela-Navarrete, R
    Raynaud, JP
    PROGRES EN UROLOGIE, 2002, 12 (03): : 384 - 394
  • [35] The oral controlled absorption system (OCAS®):: The evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
    Chapple, CR
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (07) : 20 - 22
  • [36] Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect
    Lowe, FC
    CLINICAL THERAPEUTICS, 1997, 19 (04) : 730 - 742
  • [37] COMPARISON OF THE EFFICACY OF SERENOA REPENS (SR) AND TAMSULOSIN (TAM) TREATMENT FOR PATIENTS WITH BENIGN PROSTATE HYPERPLASIA
    Hizli, Fatih
    Uygur, M. Cemil
    TURKISH JOURNAL OF UROLOGY, 2006, 32 (04): : 538 - 542
  • [38] Comparison of α-Blocker Monotherapy and α-Blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic Hyperplasia
    Joo, K-J
    Sung, W-S
    Park, S-H
    Yang, W-J
    Kim, T-H
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (03) : 899 - 908
  • [39] Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
    Zhongbao Zhou
    Yuanshan Cui
    Jitao Wu
    Rui Ding
    Tong Cai
    Zhenli Gao
    BMC Urology, 19
  • [40] Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
    Cai, Tong
    Wang, Ning
    Liang, Liye
    Zhou, Zhongbao
    Zhang, Yong
    Cui, Yuanshan
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2020, 24 (04) : 365 - 374
12345